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Diabetes mellitus (DM) is a signiﬁcant risk factor for the development of cardiovascular complications. This study was undertaken
to investigate the eﬀect of chronic administration of ethanolic extract of Eryngium carlinae on glucose, creatinine, uric acid, total
cholesterol, and triglycerides levels in serum of streptozotocin- (STZ-) induced diabetic rats. Triglycerides, total cholesterol, and
uric acid levels increased in serum from diabetic rats. The treatment with E. carlinae prevented these changes. The administration
of E. carlinae extract reduced the levels of creatinine, uric acid, total cholesterol, and triglycerides. Thus administration of E.
carlinae is able to reduce hyperlipidemia related to the cardiovascular risk in diabetes mellitus.
1.Introduction
Diabetes mellitus (DM) describes a metabolic disorder of
multiple etiologies characterized by chronic hyperglycemia
with disturbances of carbohydrate, fat, and protein metab-
olism resulting from defects in insulin secretion, insulin ac-
tion, or both [1]. The eﬀects of DM include long-term dam-
age, dysfunction, and failure of various organs. Diabetic
people present a 2–4-fold higher risk of developing cardio-
vascular disease than normoglycemic population of similar
age and sex. The cardiovascular complications attributable
to atherosclerosis are responsible for 70–80% of all causes
of death in patients with diabetes and represent more than
75% of all hospitalizations for diabetic complications [2].
The primary goal of diabetes treatment is the prevention of
macrovascular complications (myocardial infarction, heart
failure, ischemic stroke), as well as the microvascular com-
plications (retinopathy, neuropathy, and nephropathy); for
that reason, most patients require not only a good glycemic
controlbutalsotreatmentfordyslipidemia[3].Dyslipidemia
(disruption in the normal levels of lipids, mainly cholesterol
and triglycerides) is considered a major cardiovascular risk
factor in diabetes [2]. Therefore, the detection of dyslipi-
demiaanditstreatmenttoreducethecardiovascularriskand
its consequences are required in diabetic patients.
The growing need to ﬁnd alternatives for the treatment
of diabetes justiﬁes the study of medicinal plants used in tra-
ditional medicine. There are several reports about the bene-
ﬁcial eﬀects of a wide range of plants to treat diabetes. Hypo-
glycemic eﬀect was observed in extracts of plants such as
Amaranthus viridis [4]a n dPsidium guajava [5] whose eﬀects
are almost comparable with the synthetic drug tolbutamide,
while Zaleya decandra [6]h a se ﬀects equivalent to gliben-
clamide. Other plants also appear to exert their beneﬁcial
eﬀects by improving the dyslipidemia and oxidative stress
that characterize diabetes. For example, Morus indica L.[ 7]
decreases LDL-cholesterol and VLDL-cholesterol level and
increases HDL-cholesterol levels, while Phyllanthus amarus
[8] improves antioxidant status and reduces the risk of
oxidative stress.
In M´ exico,theuseofplantsfordiabetes treatmentisgen-
erallycarriedoutinanempiricalbasis.Inthisregard,itseems2 Biochemistry Research International
that many plants for diabetes treatment were originally used
for a variety of kidney disorders and most notably for their
diuretic eﬀect [9]. This study was conducted to analyze the
eﬀect of chronic administration of ethanolic extract of E.
carlinae in diabetic rats. This plant has often used in tra-
ditional medicine to treat diabetes; however there are no
studies indicating the eﬀects of its consumption. Eryngium
carlinae F. Delaroche is a perennial herb plant considered a
weed belonging to the family Umbelliferae. It is distributed
in forests of ﬁr, pine and pine-oak hillsides, and canyons,
deep soils rich in organic matter. It is distributed from 2020–
2590 meters above sea level. It is commonly known as “Frog
herb”. Decoctions of the aerial parts of the plant are used to
treat coughs, indigestion, diseases of the prostate, lipid dis-
orders, and diabetes [10]. It has been attributed healing and
diuretic properties to extracts from the plant. Other species
of Eryngium (Eryngium columnare)h a v eb e e nu s e dt ot r e a t
kidney disease, diarrhea, allergy, cough, and cancer [10].
2. Results
Therefore, the aim of this research was to determine the
eﬀect of chronic oral administration of ethanolic extract of
E. carlinae on some biochemical parameters in STZ-induced
diabetic rats.
3.MaterialsandMethods
3.1. Vegetal Material. Plant samples of Eryngium carlinae F.
Delaroche were collected in September and October, 2008, in
the region of Nuevo San Juan Parangaricutiro, Michoac´ an,
M´ exico. The plant was identiﬁed by Miguel Angel Bello-
Gonz´ alezPhD(FacultyofAgrobiology,UniversidadMichoa-
cana de San Nicol´ as de Hidalgo) genus and species preserv-
ing.AvoucherspecimenwasdepositedattheBiologyFaculty
HerbariumoftheUniversidadMichoacanadeSanNicol´ asde
Hidalgo (no. 15214). The aerial part of the plant was dried at
room temperature and pulverized.
3.2. Extract Preparation. Ethanolic extract of the plant was
prepared by adding 1,000mL of absolute ethanol to 100g of
plant powder and kept at 5◦C for ﬁve days. The extract was
then ﬁltered, concentrated in a rotary evaporator at vacuum
and at a temperature lower than 50◦C, evaporated at room
temperature, suspended in ethanol 96%, and stored in the
dark at 5◦C. The percentage yield of the dry residue was
1.27% w/w.
3.3. Animals. Male Wistar rats weighing 280–360g were
used. They were housed and maintained at room tempera-
ture with day/night cycles of 12h. They were fed with stand-
ard rodent diet and water ad libitum. We followed the rec-
ommendations of the regulatory standard for the use of
animals issued by the Mexican Ministry of Agriculture in the
paragraph of the Federal Regulations for the Use and Care
of Animals (NOM-062-ZOO-1999). This research was also
approved by the Institutional Committee for Use of Animals
of the Universidad Michoacana de San Nicol´ as de Hidalgo.
3.4. Diabetes Induction. Diabetes was induced by intraperi-
toneal administration of STZ (45mg/kg of body weight)
dissolved in citrate buﬀer (pH 4.5). Control rats were in-
jected with citrate buﬀer alone. Five days after streptozo-
tocin administration, the glucose levels were determined
to conﬁrm diabetes. Rats exhibiting blood glucose levels
>300mg/dL were considered for the study.
3.5. Experimental Protocol. Rats were randomly divided into
four groups of six rats. Group I, control (vehicle, ethanol
50%), Group II, control + E. carlinae (30mg/kg of body
weight), Group III, diabetic (vehicle, ethanol 50%), Group
IV, diabetic + E. carlinae (30mg/kg of body weight). The ex-
tract was given by oral administration using oral gavage. The
treatment was continued daily for 40 days.
3.6. Eﬀects ofE.Carlinaeon GlycemiaandBody Weight . Glu-
coseestimationwasstartedjustbeforeextractadministration
and followed every 5 days using a commercial glucometer
(Accu-Check Sensor III Glucometer) through a puncture in
the tail tip, and animal weight was recorded at a time during
the 40 days.
3.7. Eﬀects of E. Carlinae on Hematological and Biochemical
Parameters. At 40 days of treatment, the animals were fasted
overnight and sacriﬁced by decapitation. The blood was col-
lected, and serum was separated and used for biochemical
estimations. The levels of glucose, creatinine, uric acid, total
cholesterol, and triglycerides were estimated spectrophoto-
metrically using a commercial assay kit (BioSystems, Spain).
Glucosewasdeterminedmeasuringenzymaticoxidationcat-
alyzed through the Trinder reaction [11]. Creatinine was
determined by a kinetic method without deproteinization as
reported by Junge et al. [12]. Uric acid was determined by an
enzymatic photometric method using TBHBA (2, 4, 6-tri-
bromide-3-hydroxybenzoic acid). Total cholesterol was de-
termined measuring the enzymatic hydrolysis and oxidation
withtheTrinderreaction[13].Triglyceridesweredetermined
by an enzymatic colorimetric method using glycerol-3-phos-
phate oxidase [14]. Whole blood samples were used for he-
moglobin (Golden Bell, M´ exico) and glycosylated hemo-
globin (DiaSys, Germany) determinations using commercial
assay kits.
3.8. Statistical Analysis. The results were expressed as the
mean ± Standard Error (SE) of at least six independent ex-
periments. Statistical signiﬁcances (P ≤ 0.05) were deter-
mined with Student’s t-test using GraphPad Prism 5 soft-
ware.
Changes in the body weight of the rats are presented in
Table 1. In control groups, the extract did not alter the body
weight gain as this parameter increased 31% and 29% at the
endofthetreatmentinbothcontrolandcontrol+E.carlinae
groups, respectively, compared to their initial body weight.
Similarly, no diﬀerences in body weight were detected be-
tween diabetic and diabetic + E. carlinae groups throughout
the study.Biochemistry Research International 3
Table 1: Eﬀect of E. carlinae on body weight and blood glucose.
Groups
Body weight (g) Blood glucose (mg/dL)
Initial Final Day
(day 0) (day 40) 0 5 10 15 20 25 30 35 40
Control 349 ±4 456±10 102 ±4 109±13 92 ±48 9 ±19 3 ±13 86 ±49 0 ±17 74±0.08 2 ±4
Control + E. carlinae 317±12 408±17 11 ±7 116±10 97 ±49 5 ±2 105 ± 29 0 ±49 4 ±48 4 ±38 5 ±2
Diabetic 307±15 305±17 551±20∗ 423±16 411±13 549±21 535±22 580±15 538±22 530±30 571±29
Diabetic + E. carlinae 298±12 302±14 436±16∗ 372±14 365±19 475±33 373±24 410±29 405±38 566±15 537±27
Values are mean ± SE. ∗P ≤ 0.05 versus control group day 0.
Table 2: Eﬀect of E. carlinae on hemoglobin and glycosylated hemoglobin (HbA1c).
Groups Hemoglobin (mg/dL) Glycosylated hemoglobin (% HbA1c)
Control 16 ±0.73 .32 ±0.07
Control + E. carlinae 16 ±0.1N D
Diabetic 17 ±0.57 .48 ±0.08∗
Diabetic + E. carlinae 16 ±0.87 .34 ±0.04
Values are mean ± SE. ∗P ≤ 0.05 versus control group.
With regard to blood glucose levels, Table 1 shows the
records taken during the 40 days of treatment with E. car-
linae. It can be observed a signiﬁcant increase in glucose
levels in diabetic groups compared with controls at the be-
ginning of treatment. Oral administration of E. carlinae
(30mg/kg of body weight) for 40 days showed no reduction
in blood glucose.
Table 2 shows the levels of hemoglobin and glycosylated
hemoglobininthediﬀerentgroups.Theresultsshowthathe-
moglobin levels are not aﬀected by treatment with E. carli-
nae.Glycosylatedhemoglobindeterminationsshowasigniﬁ-
cantincreaseinthepercentageofglycosylatedhemoglobinin
diabeticgroupcomparedtocontrolgroup,andthetreatment
with E. carlinae did not change this behavior.
Table 3 shows the levels of glucose, creatinine, uric acid,
total cholesterol, and triglycerides in serum of all groups.
It is important to point out that these determinations were
made with animals 12h fast. The levels of glucose, uric acid,
totalcholesterol,andtriglyceridesinserumweresigniﬁcantly
increased in the diabetic group when compared to control
group. The treatment with E. carlinae decreased creatinine,
uric acid, total cholesterol, and triglycerides levels in serum
compared with the diabetic group.
4. Discussion and Conclusions
Oral administration of the ethanolic extract of E. carlinae
was conducted for 40 days in a concentration of 30mg/kg
of body weight. During the treatment it was observed that
the control group had a weight gain corresponding to age-
appropriate growth (Table 1). In contrast, the diabetic group
showed no weight gain, which is characteristic of this model
ofdiabetes,andthetreatmentwithE.carlinaedidnotchange
this tendency.
Glycemiccontrolisapriority indiabetic patientsbecause
it has relationship with a decrease in microvascular compli-
cations in diabetes [15]. In the measurements made at the
e n do ftr e a tm e n t( Table 1), there was no reduction in glucose
level in the groups that received E. carlinae. The glycohemo-
globin(HbA1)isageneraltermusedtodescribehemoglobin
that has been modiﬁed by the addition of glucose through a
nonenzymatic mechanism, and the HbA1c is one of those
glycosides compounds in particular that reﬂects average
blood glucose in patient 2 or 3 months before blood col-
lection [16, 17]. According to the United Kingdom Prospec-
tive Diabetes Study (UKPDS), each 1% reduction in glycosy-
latedhemoglobin(HbA1c)wasassociatedwitha37%reduc-
tion in microvascular complications, 18% fewer myocardial
infarction, and 21% fewer diabetes-related deaths [15]. The
results obtained from the measurement of HbA1c (Table 2)
show a clear diﬀerence between control (HbA1c 3.32%)
and diabetic (HbA1c 7.48%) group. The diabetic group that
received E. carlinae did not show signiﬁcant decrease in
HbA1c (HbA1c 7.34%). Based on this and the results from
Table 1,wecanconcludethattheethanolicextractE.carlinae
has not hypoglycemic eﬀect. However, it is noteworthy that
many of the plants that have been reported as hypoglycemic
agents are less eﬀective in severe diabetes [18], so it may be
necessarytoevaluatetheextractinanothermodelofdiabetes
to rule out completely its possible hypoglycemic action.
Diabetes leads to renal dysfunction [19]. Measurement
of creatinine can be considered as a marker of renal dysfunc-
tion.OurresultssuggestthattheadministrationofE.carlinae
in the diabetic group decreased level of creatinine (Table 3),
probably by improving renal function. The complex patho-
genesis for the development of diabetic nephropathy is not
well understood. One factor that has been associated with
renal and cardiovascular disease is serum uric acid. It has
beenfoundthatlevelofuricacidcirculatingintheupperend
of normal range concentration is an independent predictor
fordevelopmentofdiabeticnephropathy,whichsupportsthe
concept that uric acid may be involved in the pathogenesis
of diabetic microvascular complications [20]. Uric acid level
in the diabetic group is elevated compared to control group4 Biochemistry Research International
Table 3: Eﬀect of E. carlinae on biochemical parameters after oral administration during 40 days.
Groups Glucose (mg/dL) Creatinine (mg/dL) Uric acid (mg/dL) Total cholesterol (mg/dL) Triglycerides (mg/dL)
Control 85 ±60 .59 ±0.02 1.40 ±0.04 59 ± 3 153 ±18
Control + E. carlinae 79 ±30 .56 ±0.01 1.17 ±0.26 54 ± 3 128 ±7
Diabetic 359 ±8∗ 0.48 ±0.06 2.43 ±0.50∗ 78 ±6∗ 252 ±19∗
Diabetic + E. carlinae 376 ±21 0.32 ±0.02+ 1.10 ±0.33+ 46 ±6+ 115 ±7+
Values are mean ± SE of at least n = 6. ∗P ≤ 0.05 versus control group; +P ≤ 0.05 versus diabetic group.
(Table 3). Interestingly, the higher levels of uric acid in
diabetic rats are diminished signiﬁcantly by the administra-
tion of E. carlinae, which could be related to a delay in the
onsetofthecomplicationsofdiabetes,ashasbeenpreviously
suggested [20]. Abnormalities in the metabolism of lipids are
one of the most frequent complications in diabetes. Among
the most common lipid abnormalities is the elevation of
cholesterol and triglycerides. Hypertriglyceridemia has been
identiﬁed as a major risk factor for cardiovascular com-
plications [21]. Diabetic group had elevated triglycerides
level compared to control group (Table 3). This increase was
normalized by treatment with E. carlinae.W i t hr e g a r dt o
total cholesterol level, the treatment with E. carlinae was able
to reduce this level (Table 3). Based on our results we con-
clude that the ethanolic extract of E. carlinae has no hypo-
glycemic eﬀect; however, by its hypolipidemic eﬀect it could
be used as an adjuvant in the treatment of diabetes. Further
studies need to be done to characterize the active compo-
nents of the ethanolic extract of E. carlinae and its mecha-
nism of action.
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